UK Receives Experimental Drug from Japan to Address Hantavirus Outbreak on Cruise Ship
The United Kingdom has acquired supplies of the antiviral drug favipiravir from Japan to address a hantavirus outbreak linked to the Hondius cruise liner. The UK Health Security Agency confirmed the delivery, which aims to bolster treatment stocks despite the low risk of wider transmission in the UK. The outbreak, involving the Andes virus strain, has resulted in three deaths and eight confirmed cases. Favipiravir, sold under the brand name Avigan by Fujifilm's Toyama Chemical, is not licensed in the UK and is considered experimental for hantavirus treatment. The drug works by inhibiting a key enzyme necessary for viral replication. Current evidence of its efficacy against hantavirus is limited to lab and animal studies, with no strong human trial data. The World Health Organization has stated that the outbreak does not pose a pandemic threat. 
